Lately, bispecific antibody drug conjugates targeting EGFR and MET have also attracted attention in the pharmaceutical industry with multiple drugs of this kind already in early phase trials for MET-aberrant cancers (Gong, 2024). The gene discussed is MET; the disease is cancer.